For over five decades minor histocompatibility (mH) antigens have contmued to fascmate immimologists, mainly because of their minor but distinct role in transplantation but no less because of their as yet unknown nature In the 1970s lt became evident that mH antigens were recognized in a MHC restncted fashion, an important feature which was poorly understood at that time Through the innovative work on the MHC class I crystals, significant insight into the nature of mH antigens as MHC-bound peptides has recently been obtained Thanks to extensive munne and human studies, more knowledgc, though still the tip of the lceberg, has been gathered with regard to the role of mH antigen specific cytotoxic Τ cell (CTL) and helper Τ (Th) cell responses in bone marrow transplantation
In this review, we have restncted ourselves to the discussion of two main aspects of human mH antigen specific CTLs, the first being their long debated mechamstic mvolvement in the pathogenesis of graft versus host disease (GvHD) after HLA-idenücal bone marrow transplantation (BMT), the second being the molecular nature of the cell surface epitopes seen by these MHC class I restncted mH antigen specific CTLs
History and definition of mH antigens
At the begmning of this centui y, Little and Tyzzer 1 observed that the rejection of tumour grafts by mbred strains of mice was regulated by a family of 'ndependently segregating genes The Identification of Single loci responsible for tumour graft rejection became possible in 1940 when Snell outlmed a procedure for the production of so-called congemc-resistant mouse strains Mice of these congemc strains rejected tumour grafts from mbred partners as a result of ι genetic dispanty for one short donor-strain derived chromosomal Segment, thus said to contam a 'histocompatibility' (H), locus 2 One of the 13 Η loci onginally identified by Snell was the H-2 locus, which was later named the major histocompatibility complex (MHC) This name resulted from the observation that the speed with which tumour graft rejection was induced by dispanty at these histocompatibility loci vaned greatly, and that the H-2 locus was amongst the strongest (major) ones All other histocompatibility loci found to induce tumour graft rejection were grouped under the complementary name of minor hislocompatibility (mH) loci Bailey contmued the search for mH loci by usmg skm mstead of tumour graft rejection as a more sensitive histogemc measure for mH mcompatibihty
In addition to in vivo tumour and skin graft rejectioii, histomcompabitility at these mH loci was found to induce Τ cell responses which could be analyzed m vitro Bevan 3 and Simpson 4 were the first to describe cytotoxic Τ cell (CTL) responses measurable in a cell lympholysis (CML) assay after in vivo pnming across multiple or Single mH dispanties These donor stram reactive CTLs were found to recognize the lmmumzing mH antigen m a MHC class I restncted fashion and provided a powerful tool for detailed in vitro analysis of mH antigens Over 40 mH loci have been defined using Snell's and Bailey's congemc mouse strams, all sharing the common features of mducing skm or tumour graft rejection and of MHC restncted in vitro CTL responses (reviewed in 5 )
In man, the existence of mH loci became evident with the discovery of the human analogue of the munne MHC the human leucocyte antigens (HLA) by Dausset, Payne and Van Rood 6 Kidney and bone marrow grafting between mdividuals with genetic identity at the HLA genes was still observed to result in graft rejection or graft-versus-host disease (GvHD) (reviewed in 7 ) Unhke the Situation in the mouse, the Single loci responsible for these immune responses could not be isolated via histogenetic methods Instead, human mH loci were identified with Τ cell populations obtained after in vivo grafting across multiple mH incompatibilities By generatmg MHC class I restncted CTL hnes from such ιη-dividuals, the in vitro definition of Single human mH gene products commenced 7 Thus far, the efforts of several mvestigators have led to the Identification of a small number of human mH antigens.
Over the last few years the understanding of the nature of mH gene products has rapidly increased With these msights, the notion grew that the name of minor histocompatibility antigens, first mtroduced 44 years ago to describe transplantation phenomena, might raise false suggestions with respect to their nature First, the term minor mrplies relatively 'not important' In the chmcal setting of organ and bone marrow transplantation between HLA-identical, mH antigen mismatched individuals, these antigens are capable of mducing vigorous immune responses leading to graft rejection or graftversus-host disease. Secondly, the name minor histocompatibility suggests we are dealmg with a group of related loci forming the counterpart of the complex of major histocompatibility genes However, whereas the MHC gene products form a homogeneous group with respect to function, so far no
The question of how many alleles exist for each locus remains to be settled The fact that in vivo pnming is required to define any given mH antigen forms an mtnnsic complication in the study of potential allelic products, since pnming m any HLA-identical transplantation settmg is um-directional Van Eis et al made the observation that none of a panel of 100 HLA-A2 expressing individuals ever coexpressed the three HLA-A2 restncted mH antigens HA-1, HA-4 and HA-5 However, the numbers did not suffice to prove or disprove whether HA-1, HA-4 and HA-5 might represent allelic products of the same locus 9 Whereas the mH loci of congemc mice were defined as mdependently segregating umts, the CTL-based defimtion of human mH antigens does not require this Where analyzed, mH phenotypes were found to be mhented and not to spontaneously arise or disappear withm famihes 7 8 However, the MHC class I restncted recogmtion of mH antigens provided a structural hmitation confoundmg thorough segregation analysis in famihes Both Zier et al 13 and our own group 14 showed that this frustratmg prerequisite could be circumvented by msertmg the missmg MHC molecule by membrane fusion or gene transfection into cells of family members naturally lackmg the restriction molecule Using this techmque lo generate complete HLA-A2 expressing famihes, we showed that the segregation patterns of the mH antigens HA-1, HA 2, HA-4 and HA-5 are compatible with them being products of smgle genes mhented in a Mendehan fashion (Schreuder et al, in press) Τ cell response to mH antigens While MHC antigens can be recogmzed by Β and Τ lymphocytes, responses to mH antigens appear predominantly Τ cell mediated Though some reports exist on putative mH antigen specific antibodies, mainly towards the male-specific antigen H-Y, these antisera have proved to be weak or nonspecific The only solid exception is the H-3 encoded beta 2 microglobulm (ß2m) molecule which induces a strong and specific antibody response 20 The mability to measure strong Β cell responses to mH antigens and the apparent exception of the ß2m molecule can nowadays be explained by the knowledge that mH antigemc Τ cell epitopes, with the exception of ß2m, are most probably small peptides as will be discussed later Τ cell responses to mH antigens in man and mouse are charactenzed by three main features First, in vitro detection of mH antigen specific Τ cells in general requires an in vivo primmg phase followed by an in vitro boosting phase Secondly, Τ cells definmg mH antigens are MHC restncted An exception to this rule is the murme mH antigen Mls (now known to be a retroviral product 21 ) which is seen in the context of any I-A and I-E class II molecule Α third common and charactenstic feature, so far only proven to regulate Τ cell responses to murine mH antigens, is the phenomenon of immunodommance
In vivo pnming
In vitro coculture of unpnmed penpheral blood leukocytes (PBL) or spieen cells of mH antigen disparate donors, does not result in measurable prohferation in mixed lymphocyle reactions (MLR), cytotoxicity in CML assays or lymphokine production Α low frequency of mH antigen specific CTL precursors is commonly thought to underlie this phenomenon 22 Another explanation might bc that the antigen presenting cells (APC) 28 Immunodommant mH antigens have been descnbed m several modeis mvolvmg multiple dispanties, and a ranking of more or less dominant antigens has been suggested (reviewed in 5 ) Smce dommatmg and dominated antigens must be present on the same lmmumzing cells, immunodominance IS thought to be regulated by antigen competition at the level of the antigen presenting cells Though the exact mechamsm remams to be elucidated, antigen competition would be very well compatible with the recent view that mH antigen specific CTLs see peptides bound to MHC class I molecules In humans, the number of identmed mH antigens is too low to conclude whether immunodominance in general governs the Τ cell response to multiple mH antigens Assuming that, as in the mouse, the human genome has an abundancy of mH loci, some recent results by our group can at least be called suggestive From the PBL of three mdividuals, each transplanted across a multiple (and probably distmct) mH barner, CTL clones reactive to the same antigen termed HA-1 were obtamed 9 mH antigens and bone marrow transplantation Graft versus host disease (GvHD) still forms a major barner to successful bone marrow graftmg between HLA-identical as well as HLA-matched donor-recrpient pairs It is beyond the scope of this review to elaborate on the pathological manifestations of acute and chromc GvHD and the progress made by clmicians in mimmizing lts comphcations However, two GvHD nsk factors relevant to understand the impact of mH antigens m BMT are discussed below
The incidence of GvHD increases with mcreasing genetic differences between BM donor and recipient Typical in cidence values are (1) <1% for autologous graftmg and monozygotic twms, (2) 36% for HLA genotypically identical siblmgs, (3) 40% for sibhngs shanng one genotypically identical and one phenotypically identical haplotype of chromosome six, and (4) 50-79% for Α, Β, DR matched unrelated MLC-negative donors 29 The contnbution of mH antigens is lllustrated by the difference between groups 1 and 2, which is due to dispanties witbin half of the genome, for which siblmgs are expected to differ Likewise, donor-recipient mcompatibihty in group 4 cojnpared to group 2, comprr/es additional dispanties for mH antigens (total genome), plus MHC hnked loci on chromosome 6 Within each group, GvHD occurs more often when female BM is grafted into male recipients, lllustrating thf effect of an additional incompatibility for the male specific mH antigen H-Y 10 Mature donor Τ cells have been shown to be required for the development of GvHD, since pretreatment of bone marrow using Τ cell specific antibodies or by means of physical Separation almost completely prevents chnical GvHD The benefits of using Τ cell depleted BM m terms of graft-survival are reduced by the associated mcreased nsks of graft faüure, mfection and recurrence of the original disease 30 Thus, the effects of Τ cell depletion and histomcompatibihty stress the reqmrement for mature donor Τ lymphocytes reactive to the histocompatibihty antigens of the patient for GvHD to occur
Effector mechanisms in GvHD mH antigen specific CTLs
The first senes of studies performed in mice to identify the Τ cell subset responsible for the induction of anti-mmor GvHD umformly imphcated Lyt2 (CD8) expressing CTL By using BM inocula completely depleted of L3T4 (CD4) Τ cells, direct evidence was provided that CTLs on their own were sufficient to cause lethal GvHD in the B10BR into CBA multiple mH disparate model 31 The notion that CTLs might not be required nor sufficient for GvHD was first aroused by Hamilton 32 who noticed the presence ot CTLs in the spleens of BM grafted mice lackmg signs of GvHD Extensive studies subsequently performed by Korngold and Sprent and Hamilton, employing additional mH disparate strams of mice, revealed that dependmg on the genetic background (mclud ing H-2) and the mH dispanty, either the Lyt2 or the L3T4 or both Τ cell types could cause GvHD (reviewed in 33 ) Later, an analogous senes of observations was made in man The first reports by Tsoi and our own group revealed the presence of CTLs in the blood of patients undergoing GvHD, which displayed host-antigen specific MHC class I restncted lysis in vitro In these initial reports, the presence of host-reactive CTLs in the blood was found to correlate with the occurrence of acute 34 and chromc 7 GvHD, respectively However, in an extensive recent study this correlation was not confirmed v Although patients with chromc GvHD tended to develop higher and more persistent levels of anti-host CTL activity than those without GvHD, this findmg was not statistically signmcant In fact, the in vitro protocol used in which lymphocytes at several dates after BMT were boosted with pre BMT PBL in vitro, revealed host-antigen specific CTLs m all 16 patients in at least one point in time
In a very recent study by our group, the role of anti-mmor CTLs was further elucidated by quantifying the frequency of CTL precursors (CTLp) in PBL of BM recipients usmg a hmitmg dilution (LD) assay (de Bueger et al, in press) HLA identical BMT was found to mduce high frequencies of mH antigen specific CTLs detectable in the blood dunng the early phase (25-100 days) of reconstitution However, the number of CTLp against host antigens showed the same development in time in all patients (ι e high 25-100 days, falhng in time to become undetectable after 400 days), irrespective of their GvHD Status Therefore, the fiequency of recipient-reactive CTLp in PBL was found not to predict the incidence of GvHD The same conclusion was recently drawn by Perrault m a murine GvHD model lf> Usmg a LD assay, frequencies of CTLp agamst host antigens were measured in 12 strains of mice after graftmg with mH mismatched BM Spleen cells of all mice were found to contam high frequencies of hostreactive CTLs shortly after BMT, whether they developed moderate acute GvHD or not It is tempting to conclude from these murine and human studies that anti-minor CTLs are neither necessary nor sufficient for the development of GvHD However, this hypoth esis is contradicted by a large body of evidence suggestmg that CD8+ Τ cells do play a role in mducing GvHD across mH barriers Notably, GvHD in the same mouse stram combinations as analyzed by Perrault 36 had previously been shown to be caused by the CD8+ Τ cell subset 33 Hence, these recent LD studies do not negate the role of mH antigen reactive CTLs in GvHD, but rather question the chmcal value of in vitro analysis of post-BMT CTLs obtamed from the peripheral blood Further evidence in man favounng a role of CD8+ Τ cells m GvHD was provided by a recent study showmg that the mcidence of GvHD was reduced (without an mcrease m the recurrence of leukaemia) when HLA-identical BM depleted of the CD8 subset of mature Τ cells was used 37 In vitro data in support of a role of CTLs in GvHD in man were provided by Kaminsky et al 22 The frequency of recipient-reactive CTLp present in donor PBL before BMT was found to predict the seventy of GvHD after BMT However, lt must be stressed that the donor-recipient paus in this study were unrelated, HLA-matched, MLC nonreactive pairs of mdividuals Apparently, the CTLp asssay IS not sufficiently sensitive to measure sigmficant values before BMT between HLA-genetically identical mdividuals (de Bueger et al, in press ), whereas the presence of additional genetic differences in the case of HLA-matched donorrecipient pairs enables in vitro measurement of unprimed mH antigen specific CTL responses 22 These additional genetic differences may he in HLA subtypes not detected by typing or HLA linked loci, as well as in an mcreased number of incompatible mH loci
Additional effector modeis
The seemingly conlradictory results on the putative correlation between mH antigen reactive CTLs in PBL and GvHD after BMT may be explained by (1) measurement of the 'wrong' CTL population, or (2) the existence of factors, in addition to mH antigen specific CTLs, which codetermine the outcome of HLA identical BMT Under the first headmg above, the blood may not be the nght site to monitor those CTLs potentially relevant in GvHD The observed disappearance of anti-host CTLp in time in PBL could well be attnbuted to an initial penpheral expansion followed by redistnbution and migration out of the blood into the target tissues Whereas this lymphocyte traffickmg was suggested in rodent modeis, 38 to date no evidence Supports a sigmficant lymphocyte homing to the GvHD affected tissues in man v) Furthermore, the anti host CTL population quantified in vitio may compnse CTL clones reactive to all distmct host mH antigens However, some host mH antigens appear to be more 'dominant' in the mduction of GvHD than others (see mH antigen specificity of effector cells) In addition, CTLs reactive to tissue-specific mH antigens may strongly contnbute to the local GvHD phenomena, whereas the usage of Epstein Barr virus transformed Β lymphoblastoid cell lmes (EBV BLCL) or PBL as stimulator cells allows expansion and detection of only those hostreactive CTLs which recognize mH antigens on lymphoid cell types The potential relevance of target tissue specific mH antigens in GvHD is supported by the finding that in vitro responses of donor Τ cells to host epidermal cells, but not to host lymphoid cells, are predictive for the occurrence of GvHD after HLA-identical BMT 40 Also, CTLs specific for the skm specific munne mH antigen EPA-1 mflict GvHD-hke tissue destruction when injected in vivo 41 The contnbution of factors other than mH specific CTLs must be considered too It is very possible that, though no sigmficant correlation between the presence of CTLs and GvHD is measured, these anti host CTLs do indeed contnbute to the mduction and/or effector phases of GvHD In particular, lf CTLs are required but are dependent for their activity on mteraction with Th cells and soluble factors, they would not by themselves be sufficient to account for the development of GvHD The last few years evidence has accumulated that, in addition to CTLs, host antigen specific CD4+ Since GvHD does not occur m the complete absence of histocompatibihty differences, it can be anticipated that somewhere m the cascade of cellular events leading to GvHD, antigen specific Τ cells must be involved in at least one phase However, this does not exclude an important contnbution of antigen nonspecific factors such as lymphokines in the development of GvHD Convincmg data were obtained on the role of TNFa in munne and human GvHD Antibodies to TNFa could completely prevent lethal GvHD induced in mH disparate mice 45 In a GvHD-predictive assay, the in vitro GvH reactivity to host skin tissue was found to correlate with the levels of TNFa and INF7 secreted into the culture medium 46 Also, the GvHD inducing potential of some mH antigen specific Τ cell clones has been shown to correlate with the levels of TNFa clones produced in vitro 47 
Effector cells in the skin
Seeking to define the effector cell type responsible for the local pathogenesis in the target organs of GvHD, particular attention has been paid to the skin This is because the epithehum of the skm is the first and most commonly affected tissue m acute GvHD and because the infectious complications which often accompany chromc GvHD predoimnantly are caused by lesions in the skin The majonty of histopathological studies of munne and human GvHD-affected skm after graftmg with unmampulated, mH disparate BM, descnbe a moderate, but certamly not extensive, mononuclear cell mfiltrate contaming mcreased numbers of CD8 expressmg cells The common observation of mononuclear cells in close apposition to necrotizmg basal keratmocytes 48 has strongly suggested that CTL mediated lysis of keratmocytes might occur However, one recent report denies the role of CD8+ cells m the pathology of human cutaneous GvHD No sigmficant difference was observed between the absolute numbers or ratlos of lymphocyte subsets present in GvHDaffected compared to unaffected skin in 21 patients after HLA-identical BMT 39 Another group of investigators descnbed cell types other than CD8+ CTL in contact with degenerating epithehal cells in the skm of mice suffering from anti-minor GvHD 49 5() In the first of two consecutive reports a skin infiltrating cell population, termed large granulär lymphocytes, was described to express a natural küler (NK) cell marker, but none of the Τ cell markers CD4, CD8 or CD3 4 ' J In the second report, however, studymg the same B10BR into CBA minor disparate model, these skm infiltrating cells were claimed to have a distmct phenotype (1 e NK-marker, CD3 and CD8 negative but CD4 positive) 50 Some of the differences on the lymphocyte subsets proposed as effector cells in these histoimmunochemical studies may reldte to the usage of distmct and more or less well defmed antibodies Others may reflect the usage of distmct mH disparate combinations of mice as expenmental GvHD modeis The usage of bone marrow grafts selectively depleted of either the CD4 or the CD8 Τ cell subset allowed Piguet et al 51 to directly show that Τ cells of the phenotype capable of inducmg GvHD in particular mouse strains were indeed always observed in increased numbers in necrotizing skin.
Recent work by our group has revealed that some mH antigen specific CTL clones (i.e. αΗ-Y, HA-3, HA-4, HA-6 and HA-7) lysed skin epithelial cells in a MHC class I restricted, mH antigen specific fashion. 52 ' 53 These in vitro data suggest that at least some mH antigen specific CTL clones (though obtained from PBL and not from the skin itself) have the potential to serve a direct effector function in the local GvHD pathogenesis via CTL-mediated lysis of epithelial target cells. Furthermore, our preliminary results indicate that some, though not all, mH antigen specific CD4+ Th cell clones can be induced to proliferate upon coculture with intact layers of MHC class 11+ and ICAM-1+ keratinocytes (de Bueger et al, in press).
Summarizing, both cytotoxic and proliierative Τ cells might be responsible for the pathogenesis of GvHD. It has been established in murine modeis that the phenotype of the effector cells involved locally and systematically is influenced by the genetic background and the mH barrier involved. Most importantly, the mere detection of host reactive Τ cells in lymphatic organs by means of in vitro assays does not ensure their relevance as effectors in GvHD.
mH antigenic specificity of effector cells
To identify the nature of mH antigens relevant for the development of GvHD after multiple mH disparate BMT, most investigators in man and mouse have performed in vitro analysis of host-reactive Τ cell lines obtained from spieen, peripheral blood or skin from individuals suffering from GvHD. Only a few investigators have attempted to 'identify' the nature of recipient-specific, MHC restricted mH antigens. In man, we determined the reaction patterns towards a panel of 100 target cells of 12 out of 160 CTL clones obtained from five MHC class I restricted, recipient specific CTL lines. Five distinct patterns of panel recognition were found and interpreted to define distinct mH antigens. However, since long-term in vitro culturing of the CTL lines preceeded limiting dilution and not all clones per patient were analyzed, no conclusion could be drawn on the relative importance of these five mH antigens in triggering CTLs in fully mH antigen disparate BMT. In the mouse, Wettstein et al. 28 used a transplantation barrier consisting of more than 40 known BALB.C mH loci, and analyzed the specificity of generated CTL lines on target cells expressing Single (B6.C series of congenic strains) or several (CBX series of recombinant inbred (RI) strains) of the immunizing BALB.C mH loci. From the detection of H-2K b restricted CTLs with only four distinct specificities, other than the known BALB.C antigens, two main conclusions were drawn. First, mH antigens inducing CTL responses after BMT can differ from those defined by skin gtaft rejection. Secondly, the repertoire of CTLs triggered by multiple mH disparate BMT, which mimicks best the Situation encountered in man, can be reactive to only a limited number of mH antigens.
However, as discussed above, host-reactive Τ cells detectable in vitro may be present in GvHD-free animals and patients.
32 · 35 Thus, the approach used in these studies does not α priori guarantee that the Τ cell clones studied recognize 'GvHD relevant' mH antigens. This aspect was addressed in a recent study by Miconnet et al."' 1 Seven mH antigen specific Τ cell clones were generated from spieen cells of GvHD mice, expanded and analyzed for lymphokine production, mH antigenic specificity and GvHD-inducing potential upon reinjection. Three CD4+ Τ cell clones specific for the mH antigens termed Ag-I and Ag-II, each producing high levels of TNFa in vitro, induced vigorous GvHD reactions in vivo.
Two other CD4+ Τ cell clones (reactive with a mH antigen termed III) and a CD8+ cytolytic Τ cell clone (specific for Ag IV) did not. However, in trying to Interpret these results the investigators were confronted with the complication of having two unknown variables, i.e. (1) the specific mH antigens recognized and (2) the phenotype, lymphokine production, and proliferative and/or cytotoxic characteristics of the Τ cells responsible for GvH reactions in vivo. One could conclude that those mH antigen reactive Τ cells which produce TNFa are relevant in GvHD; however, one could also argue that Τ cells specific for the mH antigens I and II, but not for III and IV are relevant in GvHD.
In conclusion, despite numerous efforts, little Information is currently available on the number and molecular nature of the mH antigens governing the GvHD responses induced in multiple mH antigen disparate BMT. Striving for controllable GvHD in HLA-identical bone marrow transplantation, it would be desirable if a limited number of dominant antigens were involved, as preliminary data in the mouse have indicated.
Nature of mH antigens
Recently, the general view of the nature of mH antigens has drastically changed. It is now clear that in contrast to an MHC antigen which refers to an immunogenic glycoprotein, an mH antigen does not refer to a Single molecular entity. Instead, one should make a distinction between the Τ cell epitopes seen by mH antigen specific CTLs on one hand, and the intracellular gene products giving rise to them on the other hand. The huge Steps made in the elucidation of the 'MHC class I restricted processing pathway' 54 have led to the Suggestion that mH antigen specific CTLs recognize peptides, derived from intracellular proteins, which are processed and presented by MHC class I molecules.
mH peptides
Identification Two main lines of investigation have led to the definition of the limited number of mH peptides which are known to date. The first strategy involves the enormous task of sequencing Stretches of genomic DNA known to include the genes encoding the mH Τ cell epitope. Subsequent cellular testing of synthetic peptides generated according to the deduced protein sequences has resulted in the definition of peptides recognized by mH antigen specific Τ cell clones. 55 Using this approach CTL clones defining Mta, a maternally transmitted mitochondrial murine mH antigen, were found to recognize synthetic peptides corresponding to a polymorphic part of mitochondrial protein ND-1. 56 Hydrophobie peptides of 17-26 amino aeids in length were efficiently recognized; peptides of 12 amino aeids were moderately well recognized, whereas shorter Stretches did not sensitize target cells for recognition by anti-Mta CTL at all. The H-2 d restricted epitopes on three 'tumour negative' (tum-) variants P91, P35 and P198, generated by chemical mutagenesis of P815 cells, could be mimicked by hydrophobic peptides of 13, 11 and 11 amino aeids, respectively (reviewed in 56 ). These peptides each differed at one position from their allelic counterparts, which were not recognized by CTLs.
The second approach to identify mH peptides was developed by Rammensee and coworkers, 26 ' 57 and has since then been applied by several investigators for purification of MHC class I and class II bound peptides. The biochemical procedure involves the extraction of acid soluble low molecular weight material from cells expressing the Τ cell epitope of interest. Extraction is done of either the complete pool of acid soluble peptides present in a cell or, by including an extra affinity chromatography Step, of only those peptides naturally bound to MHC.
58 Subsequent peptide Separation on a reverse-phase column by means of HPLC yields fractions which each can be tested for containing Τ cell epitopes. Using this approach Rötschke b Τ cell epitopes was indicated by susceptibility to protease treatment and by size estimation based on HPLC elution profiles, the amino acid sequences of the cell surface epitopes of these classical mH antigens are not available yet. 57 Other investigators and our group too have demonstrated the presence of the HLA-B35 restricted hm-2 59 and the HLA-A2 restricted mH epitope HA-2 (de Bueger et al, in press) in the low MW fraction of antigen expressing acid-eluted EBV-BLCL.
In summary, hydrophobic synthetic peptides of 9-26 amino acids long are recognized by MHC class I restricted CTL specific for a number of murine mH antigens. The naturally occuring epitopes, seen by murine and human mH antigen specific CTLs can be isolated from the restricting MHC molecules by acid elution. However, thus far the amino acid sequences of these peptides have not been determined.
Processing and presentation
Little is known thus far on the molecular mechanisms involved in the intracellular generation of MHC class I restricted mH peptides. Those few data available confirm that mH peptides presumably are products of the recently defmed MHC class I pathway, analogous to viral and self-peptides.
MHC allele specificity The results by Falk et al 26 very strongly suggest that indeed the H-4 b and H-Y protein fragments mentioned above are selected and presented by MHC class I molecules. They showed that the H-4 b and H-Y peptides detected in whole cell extracts from H-2 b mice were not present in similar extracts from male and H-4 b expressing H-2 d mice, indicating a strong MHC allele dependent effect in the generation of these two mH epitopes. So far, two examples are available where mH peptides have been directly eluted from purified MHC class I molecules. In one, the H-2K d restricted turn-mH peptide P198.3 was eluted from purified H-2K d molecules. 60 Although the sequence of this natural tumour peptide could not be identified directly by Edman degradation, a synthetic peptide was identified with identical HPLC behaviour as the natural peptide, and the sequence of this synthetic mH peptide was compatible with the binding profile described for H-2K d bound self-peptides.
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In the second example the Τ cell epitope of the human mH antigen HA-2 could be eluted from the purified HLA-A2.1 (de Bueger et al, in press ). The HA-2 active HPLC fraction contained merely nonapeptides expressing a Leu at position 2 and 9, therewith confirming the motif previously described for HLA-A2.1 bound self-peptides. 58 However, all our attempts to mimick the natural HA-2 peptide by (mixtures of) synthetic peptides, generated according to the measured profile, were thus far unsuccessful. Therefore, at this stage it cannot be excluded that the natural HA-2 Τ cell epitope, demonstrated to be a peptide generated and presented by HLA.A2.1, does not follow the binding restrictions known for abundant self-peptides.
Competition An argument in favour of mH peptides following the same intracellular route as viral peptides was provided by Kuzushima. 61 It was shown that viral infection reduced a cell's potential to present mH peptides to class I restricted anti-minor CTLs. Furthermore, the drug brefeldin A, which selectively blocks transport of newly synthesized proteins from the ER, inhibited anti-virus and anti-minor target cell lysis in a similar fashion.
Transport into ER The mutant cell lines RMA-s and 721.174/T2, with a suspected defect in the Iransport of cytosolic peptides into the class I secretory pathway, 54 have been analyzed for their ability to generate and present mH peptides. In one report RMA-s failed lo present mH peptides to the appropriate MHC class I restricted CTLs.
62 However, this finding was contradicted by a study in which mH antigen specific CTL clones did recognize RMA-s cells. 63 The recent observation that RMA-s cells, though ineffectively, do present endogenous antigens, may account for this observation.
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Because of its 'leaky' phenotype these results with RMA's do not provide clear insight into the processing requirements of mH peptides. More straightforward results were obtained with the human T2 cell line. In contrast to its parental cell line Tl, it was found to be unable to present the human mH peptide HA-2 to HLA-A2.1 restricted CTLs. Likewise, T2 failed to process and present antigenic peptides from influenza following viral infection. Yet upon transfection of T2 with the rat ABC transporter cDNAs TAP-1 and TAP-2, the capacity to process and present both the mH antigen HA-2 and the influenza specific peptide for CTL recognition were restored (Momburg et al., in press ). These results indicate that peptide import into the ER is required for enabling this mH peptide to bind class I molecules. Moreover, since the signal recognition particle-mediated pathway 54 is unaffected in T2 cells, the failure to present HA-2 indicates this mH peptide may not represent a signal peptide.
mH proteins
The use of transfection modeis has revealed that proteins in all cellular compartments and of viral, foreign as well as selforigin can in principle give rise to class I associated CTL epitopes. Rammensee et al. 65 elegantly illustrated the degeneracy of intracellular localization in the ß-galactosidase model by generating transfectants producing either a glycosylated transmembrane, a cytosolic or a secreted form of the protein. All three types of transfectants presented identical peptides to H-2L d restricted CTL clones. The indicated irrelevance of glycosylation, intracellular destination and presence of signal sequences of proteins for the generation of MHC class I restricted peptides had previously been demonstrated using the influenza virus model. 66 In addition, it has become evident that proteins do not have to be newly synthesized nor do they need to be of endogenous origin. Native ovalbumin, when introduced directly into the cytoplasm, was shown to be recognized by H-2 b restricted, OVAspecific CTLs. 67 Therefore, of the two criteria used to initially describe murine mH antigens, one, the recognition by MHC class I restricted CTLs, appears to be met by many intracellular proteins. Which intracellular proteins would in principle have the potential to meet the second classical biological criterion of inducing skin graft rejection remains to be determined.
Classical mH proteins
Of the classical mH gene products, defined by skin-graft Human minor histocompaübihty antigens 35 rejection between H-2 identical congenic strains of mice, only very few have been formally defined. The 12 kD protein ß2m was found to be encoded in the H-3 region on chromosome 12.
19 This protein was classified as a mH antigen since it induces H-2 restricted CTL responses after in vivo priming, even though its potenlial to induce skin graft rejection is unclear. However, ß2m as a secreted 12 kD cell surface molecule may not be representative of mH proteins. The three known murine alleles of ß2m are recognized as integral subunits of the MHC class I cell surface complex and do not require processing or degradation for recognition by ß2m specific CTLs.
68
' 69 It has been proposed that its behaviour as a mH antigen reflects differential binding of (mH) peptides by the distinct ß2m alleles, 69 although this remains to be proven.
Α second identified mH protein is the mitochondrial transmembrane protein ND-1. This protein exists in four allelic forms differing by Single amino acids in the hydrophobic N-terminal part of the protein, and seems to give rise to epitopes recognized by Mta-specific CTLs. 56 The function of this ND-1 protein remains elusive; it is suggestive that no functional differences could be detected between carriers of the four distinct allelic forms of the protein.
The proteins giving rise to turn-peptides have not been identified. Given the fact that the sequences of the peptides recognized by turn-specific CTLs were identified (see mH peptides), the identity of their proteins was expected to be found within protein databases. However, this was not the case. Boon and coworkers have advanced two explanations for this inability to find the protein source of these peptides. Either turn-peptides originate from as yet unidentified cellular proteins or, alternatively, are directly encoded by small pieces of promotorless DNA, so-called 'peptons', and thus would not result from proteolysis of translated functional proteins. This new and provoking concept so far has not been supported by experimental evidence.
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In summary, the ubiquitous glycoprotein ß2m, involved in cell surface transport and stabilization of MHC class I molecules, and the mitochondrial transmembrane protein ND-1 of unknown function, constitute the only two proteins identified as giving rise to cell surface epitopes recognized by mH antigen specific CTLs.
'New' mH proteins Viral (regulated) proteins Α concept formulated in 1966 was that mH proteins might be encoded or regulated by retroviral genes. 71 This notion was substantiated by Wettstein 72 who described close linkage between ectotropic and xenotropic retroviral sequences and B6 mH loci. However, it could not be excluded that the observed linkage could result from random insertion of retroviral as well as mH loci in the genome. In an attempt to provide direct evidence, Colombo 73 inserted Moloney murine leukemia viral (Mulv) genes into BALB/c, C57B/6 and 129 strain embryos to generate socalled 'Mov co-isogenic' strains. Skin grafts from these Mov strains of mice were rejected by their co-isogenic partners, differing only for the inserted viral gene. The induced H-2 b restricted CTLs were shown to recognize a Mulv-derived product since Mulv-and Rauscher-virus infected background strain target cells were lysed. With these results, Colombo was the first to provide direct evidence that retroviral sequences, when introduced into the genome can result in cell surface epitopes inducing skin graft rejection and class I restricted CTL responses.
In man, virtually nothing is known about retroviral insertions in the genome. At this point the hypothesis that germline inserted (retro-) viral genes encode or regulate (some) mH proteins remains open.
Self-proteins Α second general hypothesis held by many investigators in the field of mH antigens is that polymorphic (parts of) intracellular 'seif proteins could represent mH transplantation barriers. The murine mH protein ß2m represents such a polymorphic self-protein. However, as discussed above, ß2m may be an exception since it is recognized as a whole cell surface protein instead of as a processed peptide. To test the hypothesis that a polymorphic self-protein could act as a transplantation barrier, Speiser et al. 74 made use of the known polymorphism of the murine myxovirus resistance nuclear protein MX. Indeed, skin grafts from MX proteinexpressing BALB.c mice were rejected by MX-negative BALB.c congenic partners. Furthermore, injection of MXexpressing spieen cells into MX-negative BALB.c congenic mice resulted in MX antigen specific CTL after in vitro boosting. Notably, cell surface expression of the MX protein in MX+ mice was shown to depend on Stimulation with IFN-γ.
Thus, the creation of new mH gene products has indicated that viral as well as self-proteins can fit the description of mH transplantation proteins. Proteins of (retro)viral, foreign or self-origin located in either ER, cytosol or any other organelle can give rise to peptides immunogenic to class I restricted CTL and can represent transplantation barriers. The research of the coming years will have to prove how many and which of these peptides are brought to the cell surface and which actually do represent barriers in transplantation.
Immune surveillance in healthy individuals
Shaping the Τ cell repertoire
In the thymus, immature bone marrow derived thymocytes undergo Τ cell receptor (TCR) gene rearrangements, maturation and subsequent selection. This selection process must ensure that self-reactive, potentially autoaggressive, Τ cells do not reach the periphery (negative selection). At the same time it must ensure that functionally relevant Τ cells, i.e. seif MHC restricted Τ cells specific for foreign antigens, are allowed to populate the peripheral lymphoid Organs (positive selection) (reviewed in 75 ). The now established view that mature Τ ceils recognize peptides presented in association with MHC class I and class II molecules has led to the notion that the interaction with peptide/MHC complexes might in a similar fashion regulate the development of maturing thymocytes.
According to the current model, all self-peptides including seif mH peptides, produced and presented in sufficient numbers by seif MHC molecules, will induce negative selection of the specific Τ cells. The repertoire of seif MHC restricted Τ cells which is left after negative selection to respond to pathogenic foreign antigens is therefore dependent on the composition of the set of self-peptides present. There are several examples where modification of the TCR repertoire as a result of expression of a certain mH or self-peptide could be demonstrated either by a skewed Vß usage of the remaining Τ cells, 76 or by functional deficits in the immune response to foreign antigen. 77 Mice expressing certain alleles of the murine mH antigen Mls are found to lack subsets of Τ cells using particular TCR genes. However, Mls is not considered a classical mH antigen since Mls-reactive Τ cells are found at very high precursor frequencies and are restricted by more than one MHC class II allele. For most classical mH antigens it is not known whether they induce Τ cell subsets which express only particular Vß genes. Preliminary results from our laboratory have mdicated that distmct CTL clones specific for H-Y use distinct Vß genes, even when a H-Y peptide in the context of the same MHC class I molecule was seen (Kammsky et al, unpublished observations) By contrast, several CTL clones denved from different individuals, all specific for the mH antigen HA-1, all seemed to use an identical Vß, but distmct Va and J segments (pers comm) However, even lf Τ cell responses to classical mH peptides generally involve the predominant usage of certam TCR genes, one would not expect that negative selection of these Τ cells would change the penpheral TCR repertoire m mH expressmg individuals to a measurable extent because of the low precursor frequencies of mH antigen reactive Τ cell populations in unpnmed individuals Moreover, not all 'blmd Spots' in the TCR repertoire, created as a result of expression of seif mH antigens, functionally abohsh the abihty of the individual to mount a Τ cell response to foreign antigens That the immune System can mdeed cope with such blind spots was lllustrated by an expenment of Rammensee et al Whereas the anti H-Y response in Mls-l a negative mice was mamly mediated by Vß6+ Τ cells, this response was not abrogated in MlS-l d positive mice (which lack penpheral Vß6+ Τ cells) but, instead, was mediated by Τ cells carrymg distinct TCRs
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In contrast to the potentially negative effect of inducmg blind spots, expression of seif mH antigens may contnbute in a positive fashion to the shaping of the Τ cell repertoire The presence of a distmct set of polymorphic mH peptides in each individual might allow a distinct fraction of seif MHC restncted Τ cells to mature and contnbute to the diversity of the TCR repertoire withm the species Diversity of the TCR repertoire in lts turn would positively influence the survival of the species since a broader ränge of pathogenic antigens can be recognized
Tumour surveillance
In a healthy individual all Τ cells reactive to seif mH peptides presented by seif MHC molecules will be deleted in the thymus (see above) or will be tolenzed by means of a penpheral mechamsm However, potentially autoreactive Τ cells specific for peptides denved from polymorphic selfprotems which are, under physiological conditions, not generated, are allowed to mature and can be found in penpheral blood 79 Therefore, lt IS highly hkely that mature antigen specific Τ cells will be present to recogmze mH peptides which become newly generated or overexpressed in the course of hfe For example, changes in the mtracellular protem content as a result of mduced transcnption of onco genes in a developmg tumour cell, might result in new mH peptides presented by the cell's MHC molecules The efficacy of this presently theoretical form of immune surveillance is unclear
